Skip to main content
The Journal of Biological Chemistry logoLink to The Journal of Biological Chemistry
. 2009 Mar 27;284(13):8412–8420. doi: 10.1074/jbc.M804524200

Biomechanical Regulation of Endothelium-dependent Events Critical for Adaptive Remodeling*,S⃞

Peter J Mack ‡,§,1, Yuzhi Zhang , Seok Chung , Vernella Vickerman , Roger D Kamm ¶,2, Guillermo García-Cardeña ‡,3
PMCID: PMC2659199  PMID: 19047056

Abstract

Alterations in hemodynamic shear stress acting on the vascular endothelium are critical for adaptive arterial remodeling. The molecular mechanisms regulating this process, however, remain largely uncharacterized. Here, we sought to define the responses evoked in endothelial cells exposed to shear stress waveforms characteristic of coronary collateral vessels and the subsequent paracrine effects on smooth muscle cells. A lumped parameter model of the human coronary collateral circulation was used to simulate normal and adaptive remodeling coronary collateral shear stress waveforms. These waveforms were then applied to cultured human endothelial cells (EC), and the resulting differences in EC gene expression were assessed by genome-wide transcriptional profiling to identify genes distinctly regulated by collateral flow. Analysis of these transcriptional programs identified several genes to be differentially regulated by collateral flow, including genes important for endothelium-smooth muscle interactions. In particular, the transcription factor KLF2 was up-regulated by the adaptive remodeling coronary collateral waveform, and several of its downstream targets displayed the expected modulation, including the down-regulation of connective tissue growth factor. To assess the effect of endothelial KLF2 expression on smooth muscle cell migration, a three-dimensional microfluidic assay was developed. Using this three-dimensional system, we showed that KLF2-expressing EC co-cultured with SMC significantly reduce SMC migration compared with control EC and that this reduction can be rescued by the addition of exogenous connective tissue growth factor. Collectively, these results demonstrate that collateral flow evokes distinct EC gene expression profiles and functional phenotypes that subsequently influence vascular events important for adaptive remodeling.


Coronary collateralization or arteriogenesis is a vascular adaptive remodeling process that occurs in the context of arterial occlusion when preexisting collateral arterioles remodel to form larger diameter bypass arteries. The current arteriogenesis paradigm implicates local hemodynamics, recruitment/activation of monocytes, and structural remodeling of the vascular wall as key steps in collateralization (1). Two primary stages of collateralization have been described based predominantly on observations from femoral artery ligation models that induce collateral remodeling via an instantaneous increase in collateral flow. The initial stage of collateralization is characterized by a wave of monocyte-driven inflammation and rapid vasodilation, an immediate compensatory response to increased collateral flow. In the second phase of collateralization, the initial inflammatory response is resolved, and the newly formed conductance artery wall is stabilized (2). To date, considerable attention has been dedicated to investigating the inflammatory regulation of this process (i.e. MCP-1 and GM-CSF), but despite evidence on the importance of the endothelium and endothelium-derived factors in flow-mediated arterial remodeling (35), less is known about how altered collateral vessel shear stress acting on the endothelium affects collateralization. Characterizing the specific role collateral flow plays in regulating functional endothelial cell phenotypes, and endothelium-dependent processes associated with adaptive remodeling should therefore provide a framework to better understand the establishment, maintenance, and remodeling of arteries.

A number of signaling molecules have previously been characterized for their role in controlling smooth muscle cell phenotypes in both blood vessel maturation and vascular remodeling. For example, mice lacking platelet-derived growth factor B, S1P1 (sphingosine-1 phosphate-1), or KLF2 (Kruppel-like factor 2) are embryonic lethal due to defects in vascular wall formation and function (611). Models of arterial injury have also identified matrix-altering factors (namely transforming growth factor β (TGF-β)4 and bone morphogenic proteins) as critical in regulating smooth muscle cell proliferation and migration, and evidence exists indicating that the endothelium contributes to the in vivo production of these factors (1214). Furthermore, constitutively active angiopoietin 1 signaling through its endothelial receptor Tie2 has been shown to lead to vascular wall hyperplasia (15). Consistent with many of these in vivo observations are experiments using endothelial cell (EC)-smooth muscle cell (SMC) co-culture and conditioned medium assays that have deduced that EC can generate signaling molecules required for SMC differentiation and migration (16, 17). More recently, experimental models of EC-SMC co-culture have incorporated the additional capability to apply flow to the endothelium in order to investigate this biomechanical effect on EC-SMC interactions (1820).

Endothelial mechano-activation by hemodynamic shear stress is widely recognized as essential for regulating physiological and pathological vascular functions (2124). To address the question of how elevated collateral flow acting on the endothelium affects adaptive remodeling processes, we developed previously undefined numerical simulations of the shear stress waveforms present in coronary collaterals and used these waveforms to characterize the effect of collateral flow on EC gene expression and the subsequent flow-mediated endothelial paracrine effects on SMC molecular phenotype. Finally, using a novel three-dimensional microfluidic device that supports heterotypic vascular cell culture, we show that collateral flow-mediated EC genes significantly influence SMC migration, a critical process occurring throughout the different stages of collateralization (25).

EXPERIMENTAL PROCEDURES

Lumped Parameter Numerical Simulation of Collateral Vessel Shear Stress Waveforms—A lumped parameter hemodynamic model was created to numerically simulate shear stress waveforms acting along the no stenosis/normal coronary collateral (NCC) and partial stenotic/adaptive remodeling coronary collateral vessels (ACC). A number of assumptions were made for the simulations based on what is currently known regarding the geometric parameters of the coronary collateral circulation. First, a bridging lesion geometry was assumed in which the coronary collateral vessels originate proximally and terminate distally to the site of occlusion in the same vessel (see parallel vessel segments in Fig. 1, A and B). This common collateral geometry has been observed in greater than 20% of patients with developed coronary collaterals (26). Next, since both the collateral size and distribution (i.e. number of collateral vessels bypassing a stenosis) have been demonstrated to vary in patients and between sites of stenosis (26), we assumed a predeveloped collateral diameter of 200 μm, which is consistent with human arterioles, with flow distributed across 10 parallel collaterals. Last, a concentric, 60% coronary artery stenosis (radius reduction) was assumed based on the clinical range of a critical stenosis and what is feasible to reproduce experimentally (27).

FIGURE 1.

FIGURE 1.

Numerical simulation of human coronary collateral hemodynamics. A, schematic of a bridging type collateral vessel bypassing a site of coronary stenosis. B, a lumped parameter model of the coronary circulation, inclusive of coronary collaterals in parallel with a site of coronary stenosis, was used to simulate the shear stress waveforms present in collateral vessels. The model assigns electrical circuit equivalents to each vascular segment (i.e. vascular resistance (R) and compliance (C)) and uses the appropriate pressure (P(t)) boundary conditions to solve for the pressure difference across each segment, which is then used to obtain the time-varying wall shear stress acting along each segment. Both an NCC waveform, where the resistance through the stenosis (Rst) equaled the resistance through the main coronary artery (Rmca)(C), and an ACC waveform, where the resistance through the stenosis (Rst) was equivalent to a 60% radius reduction of the main coronary artery (D), were generated with the model. The two waveforms are pulsatile over one cardiac cycle, with the NCC waveform having a mean shear stress value of 0.7 dyne/cm2 and the ACC waveform having a mean shear stress value of 12.4 dyne/cm2. Time-varying pressure tracing boundary conditions for the aorta (Paorta), right atrium (Pra), and left ventricle (Plv), which was used to calculate an external pressure, Pext = 0.75 × Plv, were obtained from Heldt et al. (28).

With boundary pressure tracings obtained from previously published data, fourth order Runga-Kutta numerical integration (Matlab; Mathworks) was used to solve for the individual time-varying nodal pressure tracings (see supplemental material) (28). These results were then used to calculate the instantaneous pressure difference across each vessel segment, ΔP, for both the NCC and ACC simulations, and subsequently the wall shear stress τ acting along the collateral vessel by the equation,

graphic file with name M1.gif (Eq. 1)

where r represents the vessel radius, and L is the vessel length (see supplemental material for detailed description of the simulation calculations).

Endothelial Cell Culture—Primary human umbilical vein EC were isolated, cultured, and subjected to shear stress waveforms, as previously described (29). Reduced serum and growth factor medium was used for the shear experiments (Medium-199, supplemented with 2% fetal bovine serum, 2 mm l-glutamine, 100 units/ml penicillin plus 100 μg/ml streptomycin, and 2.8% dextran (Invitrogen)) with a viscosity of 2.2 Centipoise (0.0022 Pascal/seconds). Shear stress application to EC using the NCC and ACC shear stress waveforms was performed using a dynamic flow system (29). For the induction of KLF2 expression, EC were plated at a cell density of 60,000 cells/cm2, and the next day they were infected with a KLF2-GFP adenovirus (EC-KLF2) or a control GFP adenovirus (EC-GFP) at a multiplicity of infection of 20. Alternatively, for the connective tissue growth factor (CTGF) luciferase activity assays, EC were plated at a density of 20,000/cm2 and grown overnight. The next day, cells were simultaneously transfected with 1.4 μg of a luciferase construct (pGL3 basic; Promega) driven by ∼2.0 kb of the CTGF proximal promoter (–2065 to +72 bp, provided by Dr. Eugene Chen, University of Michigan (30)) and 0.6 μgof β-galactosidase, for normalization, using FuGene6 (Roche Applied Science). 24 h later, the EC were infected with the KLF2 or control adenovirus as described above. After an additional 24 h, the CTGF promoter activity was analyzed.

Smooth Muscle Cell Culture and Delivery of Conditioned Medium—Human aortic vascular SMC (CRL-1999; ATCC) were grown and propagated in complete growth medium according to the supplier's instructions. For experiments in which conditioned medium containing flow-mediated endothelium-derived factors was continuously delivered to SMC, 100,000 SMC were plated on 0.1% gelatin (Difco)-coated glass coverslips (25 × 75 mm, number 1; Belco) 24 h prior to exposure to conditioned medium and maintained in serum-free medium (complete growth medium with the 10% fetal bovine serum removed) at 37 °C and 5% CO2. On the day of experimentation, ACC and NCC shear stress waveforms imposed on EC were initiated in the dynamic flow system 1 h prior to connecting to the downstream SMC culture chamber via 1% bovine serum albumin (BSA; Sigma)-coated Tygon tubing. “No endothelium” control experiments were conducted with SMC grown and maintained in the same culture chamber but in the absence of upstream EC.

Transcriptional Profiling—Labeling, hybridization, and scanning of microarrays for ACC versus NCC flow-stimulated EC transcriptional profiling were performed according to the manufacturer's protocols for the ABI1700 microarray system using total genome microarrays containing 30,096 spots representing 28,790 distinct genes (Applied Biosystems) and as previously described (31). The microarray raw signal values were filtered for signal/noise quality and normalized using Lowess regression. Differential regulation of NCC and ACC flow-mediated genes was then analyzed in custom-designed Matlab (Mathworks) software for significance using three replicate experiments and Z-pool statistical methodology, defining statistically significant gene regulation for p < 0.001 (32). Differentially regulated genes were then sorted by biological function using the publicly available Panther data base (available on the World Wide Web; Applied Biosystems) and cross-referenced with the Gene Ontology classification (available on the World Wide Web). The microarray data were submitted as a data set series to the Gene Expression Omnibus (GEO) (accession number GSE11583).

RNA Preparation and Reverse Transcription-PCR Analysis—Total RNA from EC and SMC used for real-time PCR was isolated using Lysis Buffer (Applied Biosystems) and purified using the Prism Nucleic Acid Prep-Station (Applied Biosystems) according to the manufacturer's instructions. RNA quantity was measured by spectrophotometric analysis at 260 nm, and quality was verified by an Agilent 2100 Bioanalyzer with RNA 6000 Nano LabChip kit. Purified, DNase-treated RNA (0.375 μg) was reverse-transcribed using a MultiScribe-based 25-μl reaction (Applied Biosystems). The cDNA was diluted in 50 μl of DNase-free water and subjected to a 20-μl real time TaqMan quantitative PCR (Applied Biosystems 7900).

Microfluidic Device Fabrication—The microfluidic system was made of polydimethyl siloxane (Silgard 184; Dow Chemical) using soft lithography with SU-8 patterned wafers as described by others (33). The fabricated devices were autoclaved and then plasma-treated for 60 s (Harrick) in air and bonded with sterile number 1 circular glass coverslips (VWR) to form closed microfluidic channels. The bonded devices were maintained at 80 °C for 10 min to enhance bonding strength, and then a 0.1% poly-d-lysine (Sigma) coating solution was introduced into the channels and incubated at 37 °C and 5% CO2 overnight. After coating, the devices were washed twice with sterile water and dried at 80 °C for 24 h, rendering the channel surfaces hydrophobic. Scaffold material, 0.25% type I collagen (BD Biosciences), was injected into the three-dimensional device region and incubated for 30 min at 37 °C in order to form a three-dimensional hydrogel scaffold for cell invasion. Once the scaffold formed, 0.1% gelatin was then introduced into the microfluidic channels and incubated at 37 °C and 5% CO2 for 60 min to make the channel suitable for cell seeding. The gelatin was then replaced by cell culture medium and allowed to equilibrate for 2 h at 37 °C at 5 % CO2 before cell seeding.

Three-dimensional Migration Assay Cell Seeding and Quantification—24 h after adenoviral infection, EC were seeded via one channel of the three-dimensional microfluoridic device (μFD) at a density of 2 × 106 cells/ml in complete endothelial growth medium-2 (EGM-2; Cambrex) and maintained for 24 h at 37 °C at 5 % CO2. 2 h prior to SMC seeding, EGM-2 in the microfluidic device was exchanged for co-culture medium (Medium-199, supplemented with 2% fetal bovine serum, 2 mm l-glutamine, 100 units/ml penicillin plus 100 μg/ml streptomycin, and 0.03 mg/ml endothelial cell growth supplement) in order to allow the three-dimensional region to equilibrate with the co-culture medium. SMC were subsequently labeled with the fluorescent membrane stain PKH26 (Sigma) according to the manufacturer's instructions and seeded in the channel opposing the endothelial channel at a density of 500,000 cells/ml. The EC/SMC co-culture was then maintained at 37 °C and 5% CO2 for 48 h before quantification and analysis of SMC migration. For connective tissue growth factor (human recombinant CTGF; Invitrogen) migration studies, the devices were fabricated, and the collagen gel was introduced as described above. However, SMC were seeded on the same day as collagen hydrogel injection following 0.1% gelatin coating directly in the co-culture medium described above.

SMC three-dimensional invasion for both co-culture and CTGF migration experiments was quantified by staining cell nuclei with DAPI after 48 h of migration. Briefly, the cells were fixed in 4% paraformaldehyde for 60 min at room temperature, permeabilized with 1% Triton-X for 45 min at room temperature, and DAPI-stained overnight at 4 °C in phosphate-buffered saline containing 0.1% fetal calf serum. Fluorescent images of cell nuclei and PKH26-stained SMC were then obtained for the entire three-dimensional hydrogel region using an inverted epifluorescent microscope (Nikon Eclipse TE2000-U) and a CCD camera (Sanyo VCB-3524). By merging the two images of different wavelength, nuclei of the prelabeled SMC could be distinguished from the EC, along with the coordinate position of each SMC within the three-dimensional hydrogel (MetaMorph). The distribution of cell number versus three-dimensional invasion/migration distance and total number of invading cells after 48 h of co-culture was quantified using this tracking approach.

Gel Shift Studies—To perform the gel shift studies, a nonradioactive LightShift™ chemiluminescent electrophoretic mobility shift assay kit (Pierce) was used according to the manufacturer's instructions. Briefly, multiple 5′-biotin-labeled 25-mer DNA oligonucleotide sense and antisense strands were generated from sequences of the CTGF proximal promoter (∼2 kb) that encompass the canonical CACCC KLF binding sites (34), with three of the five strands containing a single CACCC site and two of the strands containing two sites in tandem. The sense strands generated were as follows: –119 to –95 (5′-biotin-aggcaggaaggtggggaggaatgcg-3′); –844 to –820 (5′-biotin-tgttcccaccctgacacccagagcc-3′); –1085 to –1061 (5′-biotin-tcatagatgtgtggggagtcactaa-3′); –1188 to –1164 (5′-biotin-catctgcacacacccagggagaata-3′); and –1730 to –1706 (5′-biotin-cagagggcacccccacccctttgct-3′). The sense and antisense strands were annealed to generate double-stranded, biotin-labeled probes. To perform the electrophoretic mobility shift assay, 80 fmol of biotin-labeled probes were incubated with 80 ng of purified human KLF2 protein fused to glutathione S-transferase (GST-KLF2; C-terminal amino acids 265–356 with stop codon at amino acid 356), 50 μg/ml poly(dI-dC), 2.5% glycerol, 0.05% Nonidet P-40, 5 mm MgCl2 in the presence of binding buffer (10 mm Tris-HCl, pH 7.5, 50 mm KCl, 1 mm dithiothreitol) for 20 min at room temperature. After incubation, the DNA-protein complexes were separated by 5% nondenaturing polyacrylamide gel electrophoresis (Bio-Rad) and transferred to a positively charged nylon membrane (Pierce). After UV cross-linking, detection was performed with streptavidin-horseradish peroxidase conjugate following the manufacturer's protocol (Pierce).

Statistical Analysis—Statistical significance was determined by one-way analysis of variance for experiments with more than two subgroups, whereas post hoc and pairwise comparisons were performed by two-tailed Student's t test for all others (Primer of Biostatistics). p values less than 0.05 were considered significant. Statistical significance for the microarray data is described under “Transcriptional Profiling.”

RESULTS

Hemodynamic Simulation of Coronary Collateral Shear Stress Waveforms—A lumped parameter model was developed to compute the shear stress waveforms imposed on coronary collateral endothelium (Fig. 1, A and B). The goal of the model was to numerically simulate collateral vessel shear stress waveforms in the normal coronary collateral (designated NCC) when there is no stenosis and in the adaptive remodeling coronary collateral (designated ACC), corresponding to a 60% radius reduction of the upstream main coronary artery. Assigning previously published (35) or fluid dynamically estimated parameters (i.e. vascular resistance (R) and compliance (C)) to each vessel segment of the coronary circulation and applying the corresponding pressure tracing, Pi(t), boundary conditions (28) (see “Experimental Procedures” and supplemental material) to the NCC and ACC models yielded two distinct pulsatile collateral vessel waveforms (Fig. 1, C and D, respectively). These simulations represent two previously undefined collateral waveforms that provide an estimate of the biomechanical shear stress experienced by both a normal collateral vessel and a collateral vessel undergoing adaptive remodeling.

Collateral Shear Stress Regulates Endothelial Gene Expression Patterns—The two simulated coronary collateral waveforms were next applied to cultured human umbilical vein EC for 24 h, and differences in the resulting EC molecular phenotype were determined by genome-wide transcriptional profiling. In total, 681 genes were found to have statistically significant regulation, as determined by Z statistics (32) (Fig. 2A). Further analysis revealed the differential regulation of multiple endothelial genes that have previously been shown to influence both acute and chronic vascular adaptations in the developing embryo and the adult (Table 1). This collateral flow-mediated endothelial gene expression pattern included the differential regulation of vasoactive, angiogenic, inflammatory, extracellular matrix, developmental, secreted, and transcription factor genes. Specifically, ACC flow up-regulated expression of vasodilatory genes (ENOS (endothelial nitric-oxide synthase) and VIP (vasoactive intestinal peptide)), endothelial receptors and ligands required for arterial development (TIE2 (endothelial tyrosine kinase receptor) and JAG1 (jagged 1)), extracellular matrix regulators (NOV (nephroblastoma-overexpressed) and TIMP3 (tissue inhibitor of metalloproteinase 3)), and transcription factors (KLF2, KLF10, KLF13, and FOXF1 (forkhead box f1)). Conversely, ACC flow down-regulated endothelial genes involved with angiogenesis/wound healing (ANGPT2 (angiopoietin 2), FBLN5 (fibulin 5), IL8 (interleukin-8), CTGF, CYR61 (cysteine-rich 61), SEMA3A (semaphorin 3A), TGFB2 (transforming growth factor β2), and NRP1 (neuropilin 1)), inflammation (MCP-1 (monocyte chemotactic protein 1), IL8 (interleukin-8), BMP4 (bone morphogenic protein 4), and BMP2 (bone morphogenic protein 2)), transcription (FOXO1A (forkhead box o1a)), and vasoconstriction (END1 (endothelin 1)).

FIGURE 2.

FIGURE 2.

Collateral flow regulates vascular cell molecular phenotypes. A, application of the simulated coronary collateral waveforms to cultured human EC resulted in genome-wide differences in endothelial transcriptional profiles. Significant differences across three independent samples were determined statistically for p < 0.001, using a z-statistic method of pooled variances (32). Normalizing ACC gene expression to NCC yielded 267 significantly up-regulated genes (red) and 414 significantly down-regulated genes (blue). B, real time TaqMan PCR validation of select differentially regulated genes identified by the transcriptional profiles as having a potential role in adaptive remodeling. EC conditioned medium from the simulated ACC compared with the NCC waveform and a no endothelium control increased SMC gene expression of MYOCD (C) and decreased the expression of MMP-3 (D), as determined by real time TaqMan PCR. E, ACC flow-mediated EC conditioned medium delivered to SMC also increased the expression of myocardin-dependent SMC genes, including CNN1 and αSMA, compared with NCC flow-mediated EC conditioned medium. Data represent the mean of four independent experiments. All error bars show S.E.; *, p < 0.05; **, p < 0.01.

TABLE 1.

Differential expression of collateral flow-mediated endothelial genes identified by transcriptional profiling and associated with adaptive remodeling

RefSeq Gene name; symbol -Fold change Remodeling function
Up
    NM_002514.2 Nephroblastoma overexpressed gene; NOVa 26.5472 Matricellular protein; ECMb protein
    NM_194435.1 Vasoactive intestinal peptide; VIP 4.7390 Vasodilation; secreted peptide
    NM_016270.1 Kruppel-like factor 2 (lung); KLF2 4.5575 Vasoprotection; transcription factor
    NM_000362.3 Tissue inhibitor of metalloproteinase 3; TIMP3 3.7926 Anti-angiogenesis; ECM remodeling
    NM_000603.3 Nitric-oxide synthase 3 (endothelial cell); ENOS 2.9320 Vasodilation
    NM_000459.1 Tyrosine kinase, endothelial; TEK/TIE2 2.6057 Vascular development; receptor
    NM_00214.1 Jagged 1 (Alagille syndrome); JAG1 2.2904 Vascular development; Notch ligand
    NM_002006.3 Fibroblast growth factor 2 (basic);FGF2 2.2724 Angiogenesis/arteriogenesis; secreted
Down
    NM_003873.2 Neuropilin 1; NRP1 -2.1897 Angiogenesis; secreted
    NM_003239.1 Transforming growth factor, β2; TGFB2 -2.1517 Wound healing; secreted
    NM_001554.3 Cysteine-rich, angiogenic inducer, 61; CYR61 -2.2162 Angiognesis; secreted
    NM_130851.1 Bone morphogenetic protein 4; BMP4 -2.5047 Inflammation; secreted
    NM_006080.1 Semaphorin 3A; SEMA3A -2.5114 Angiogenesis; secreted
    NM_001200.1 Bone morphogenetic protein 2; BMP2 -2.5437 Inflammation; secreted
    NM_001901.1 Connective tissue growth factor; CTGF -2.6762 Wound healing; secreted
    NM_001955.2 Endothelin 1; EDN1 -3.0242 Vasoconstriction; secreted
    NM_000584.2 Interleukin 8; IL8 -3.5467 Inflammation; cytokine
    NM_006329.2 Fibulin 5; FBLN5 -3.6664 Angiogenesis; ECM protein
    NM_002983.2 Chemokine (C-C motif) ligand 2; CCL2 (MCP-l) -4.6387 Inflammation; cytokine
    NM_001147.1 Angiopoietin 2; ANGPT2 -9.9658 Angiogenesis; secreted
a

Underlined genes are previously defined transcriptional targets of KLF2 (31).

b

ECM, extracellular matrix.

The collateral flow-mediated transcriptional profiling data, cross-referenced with previously published endothelial microarray data sets from our laboratory, also revealed that a significant proportion of these collateral flow-mediated genes, both up- and down-regulated, are transcriptional targets of the endothelial transcription factor KLF2 (genes underlined in Table 1) (31). Additional transcription factors were also found to be differentially regulated by the collateral waveforms (see supplemental material), and none of the ones up-regulated by the ACC waveform displayed as substantial published evidence as KLF2 for controlling the formation and maintenance of the vessel wall (7, 10). Thus, KLF2 emerged from the analysis as a collateral flow-regulated transcription factor that may act as a central regulator of endothelium-dependent events critical for adaptive arterial remodeling. The up-regulation of KLF2 by the ACC waveform was confirmed by TaqMan real time PCR along with several genes that have previously been shown to be dependent on KLF2 expression, including the up-regulation of TIE2 (endothelial tyrosine kinase receptor) and NOV (nephroblastoma-overexpressed) and the down-regulation of the vascular destabilizing/proangiogenic genes ANGPT2 and CTGF (Fig. 2B) (31). Collectively, these transcriptional profile expression patterns demonstrate that collateral flow promotes a distinct endothelial molecular phenotype associated with mature, arterial vessels and provide a comprehensive collection of collateral flow-mediated endothelial genes that may exert a regulatory role in adaptive remodeling.

Collateral Flow Acting on the Endothelium Regulates Smooth Muscle Cell Gene Expression—In order to determine whether the simulated collateral flow waveforms acting on EC have paracrine ability to differentially regulate smooth muscle gene expression, we developed a system that supports the culture of human aortic smooth muscle cells (SMC) while receiving flow-mediated EC conditioned medium (see supplemental material). The SMC culture system was continuously perfused throughout the duration of the collateral flow experiments and did not allow direct contact between EC and SMC, ruling out effects mediated by cell-cell interactions. With this system, exposure of SMC to ACC flow-mediated EC conditioned medium for 24 h resulted in increased SMC expression of MYOCD (myocardin), a transcriptional co-activator essential for the expression of multiple SMC contractile proteins (36, 37) (Fig. 2C), and a decrease in SMC expression of MMP-3 (matrix metalloproteinase 3), a matrix-degrading enzyme whose expression is associated with pathologic changes to the vessel wall (Fig. 2D) (38, 39), compared with SMC exposed to NCC flow-mediated EC conditioned medium or no endothelium control medium. Importantly, CNN1 (calponin) and αSMA (α-smooth muscle actin), two SMC genes that are downstream transcriptional targets of myocardin (36), were also increased in SMC exposed to ACC, compared with NCC, flow-mediated EC conditioned medium (Fig. 2E). Thus, by coupling the simulated collateral waveforms with dynamic EC-SMC co-culture, these results demonstrate that collateral flow acting on EC has the capacity to modulate the expression of SMC genes and suggest that flow acting on the endothelium is an important determinant of vascular SMC phenotype during adaptive remodeling.

Collateral Flow-mediated EC Genes Control SMC Migration—SMC migration is a critical event during embryonic blood vessel formation and adult vascular disease processes, such as atherosclerosis, restenosis, and arterial bypass vein grafting in response to changes in the vessel microenvironment (36, 40). Accordingly, we next sought to characterize how endothelial genes evoked by collateral flow regulate SMC migration, an effect that may have functional implications for adaptive remodeling. In particular, we chose to focus on KLF2, because multiple collateral flow-mediated endothelial genes (Table 1) have previously been shown to depend on KLF2 (31), and KLF2 has been documented as critical for vascular wall development and function (7, 8, 10). In order to characterize the effect of endothelial KLF2 expression on SMC migration, we developed a three-dimensional μFD assay to monitor SMC migration in response to EC-generated factors while in co-culture or in response to exogenous factors while in monoculture. The three-dimensional μFD used here was a polydimethyl siloxane microfabricated system containing two independent flow channels separated by symmetric 1300 × 500 × 150 μm three-dimensional central regions that were filled with a hydrogel scaffold (type I collagen) (Fig. 3, A–C). Therefore, cells seeded within the individual flow channels can invade the three-dimensional hydrogel and communicate via paracrine signals transported across the hydrogel region (41).

FIGURE 3.

FIGURE 3.

EC expressing KLF2 inhibit EC-directed SMC migration. A and B, a three-dimensional μFD assay was designed in order to investigate SMC migration in response to endothelium-derived factors. The device has two independent flow channels with each channel separated by a three-dimensional region filled with a hydrogel scaffold. C, SMC were cultured in the three-dimensional μFD in co-culture with EC. A type I collagen scaffold was injected into the three-dimensional region, and cells were introduced into their respective channels (smooth muscle channel and endothelial channel). Factors generated by EC were transported across the scaffold by passive diffusion. The image is shown at 4× magnification and rotated 90° relative to schematics shown in A and B. The cumulative effect of KLF2-dependent EC factors act to inhibit EC-directed three-dimensional SMC migration. Shown are 10× magnification fluorescent images of no endothelial control (NoEC) (D), endothelial cells expressing GFP only (EC-GFP)(E), and endothelial cells expressing KLF2 (EC-KLF2)(F). Blue, nuclei (DAPI); red, SMC (PKH-26 membrane stain). G, histogram quantification of the SMC migration distance into the three-dimensional region for the three culture conditions revealed that EC co-culture increases SMC migration compared with no endothelial control and that this effect is abolished by KLF2 induction in EC, as shown by quantifying the total number of SMC invading the three-dimensional area after 48 h (G, inset). Data are reported as the mean of 10 (EC-GFP and EC-KLF2) and nine (NoEC) independent experiments, with error bars representing S.E.. *, p < 0.05 across all conditions; ‡, p < 0.05 pairwise comparison between NoEC and EC-GFP only.

The effect of EC KLF2 expression on SMC migration was characterized by co-culturing SMC with KLF2 adenovirus-infected EC in opposite channels of the three-dimensional μFD. SMC migration and invasion into the three-dimensional region was compared between three co-culture conditions: no endothelium (NoEC; Fig. 3D), GFP control adenovirus (EC-GFP; Fig. 3E), and KLF2-GFP adenovirus (EC-KLF2; Fig. 3F). Quantification of three-dimensional SMC migration for the three co-culture conditions revealed that a significantly greater number of SMC invaded the three-dimensional region during co-culture with EC-GFP compared with both the no endothelium and EC-KLF2 co-culture conditions, reported as a histogram distribution of cell number versus migration distance (Fig. 3G), as well as the total number of SMC migrating into the three-dimensional space (Fig. 3G, inset). There was no significant difference when comparing SMC migration in co-culture with noninfected EC to control GFP-expressing EC (data not shown). These three-dimensional SMC migration results demonstrate that the integrative effect of KLF2 expression in EC acts to reduce SMC migration and provide insight into the molecular program used by endothelial cells to control SMC migration.

We next sought to characterize a KLF2-dependent endothelium-derived factor that may account for the observed modulation in three-dimensional SMC migration and focused on CTGF, since it is an EC gene that was found to be down-regulated by the ACC waveform (Fig. 2B). Additionally, CTGF has been shown by others to stimulate migration in multiple cell types (42, 43) and exist at high levels in atherosclerotic lesions, a focal site of vascular disease associated with increased smooth muscle cell migration (44). First, we documented that adenovirus-mediated KLF2 expression in EC (EC-KLF2) reduces endogenous CTGF expression compared with control adenovirus-infected EC (EC-GFP) (Fig. 4A). Consistent with this observation, we also found CTGF promoter activity to be reduced in EC-KLF2 compared with EC-GFP as well as noninfected EC (EC-Only) (Fig. 4B). This result was achieved by employing a luciferase-based activity assay using ∼2.0 kb of the CTGF proximal promoter (30), which contains several putative KLF binding sites. Finally, using a gel shift assay and probing for the five 25-bp segments of the 2.0-kb CTGF proximal promoter containing canonical CACCC KLF binding sites, we demonstrated that KLF2 binds only to the CTGF proximal promoter sequence between base pairs –1730 and –1706 (Fig. 4C).

FIGURE 4.

FIGURE 4.

CTGF expression is reduced by KLF2 and induces SMC migration. Adenovirus-mediated endothelial KLF2 expression (EC-KLF2) reduces endogenous CTGF gene expression compared with control adenovirus-infected EC (EC-GFP), as determined by real time TaqMan PCR (A) and CTGF transcriptional activity compared with EC-GFP and negative control EC (EC-Only), as determined by a luciferase activity assay using an ∼2.0-kb fragment of the CTGF proximal promoter (B). The binding of KLF2 to the CTGF promoter was documented using a gel shift assay, with GST-KLF2 binding observed in only one (–1730 to –1706) of the five (25-bp) probes tested from the CTGF proximal promoter (C). All of the probes contained either one or two canonical CACCC KLF binding sites. D, 10× magnification fluorescent images of control (right) and 10 μg/ml CTGF (left) three-dimensional SMC migration. Blue, nuclei (DAPI); red, SMC (PKH-26 membrane stain). E, quantification of the total number of SMC invading the three-dimensional region after 48 h showed that CTGF induced more SMC migration compared with control. F, the addition of 10 μg/ml CTGF to the EC channel of the EC-KLF2 co-culture with SMC restored SMC migration to EC-GFP levels, as shown by normalizing the number of SMC migrating in each test condition to the number migrating in the EC-GFP co-culture condition. Data are reported as the mean of three (A), four (E), or five (B and F) experiments with error bars representing S.E.; *, p < 0.05. NS, not significant.

Once establishing that KLF2 acts to inhibit CTGF transcription and gene expression, the effect of exogenous CTGF on three-dimensional SMC migration was evaluated. 10 μg/ml CTGF was first administered in the absence of EC to the channel opposite of SMC with the three-dimensional μFD migration assay. Quantification of the resulting three-dimensional SMC migration revealed that CTGF significantly increases the total number of SMC migrating into the three-dimensional region after 48 h compared with control (Fig. 4, D and E). Moreover, delivering CTGF at the same concentration to the endothelial cell channel in the presence of EC expressing KLF2 (EC-KLF2) was able to restore three-dimensional SMC migration levels to that of SMC co-cultured with control EC (EC-GFP) (Fig. 4F). These results show that KLF2 regulates CTGF expression at the transcriptional level and indicate that CTGF is a KLF2-dependent EC factor capable of influencing SMC migration. Taken together, these three-dimensional SMC migration findings suggest that the gene expression changes evoked by collateral flow during coronary collateralization (e.g. ACC waveform) act to limit SMC migration, which may have important implications for the vessel wall structure during flow-mediated adaptive remodeling.

DISCUSSION

Environmental cues, circulating humoral factors, and locally produced signals all influence the function and structure of a remodeling vessel (45). In this study, we combined numerical simulation with molecular and functional vascular cell phenotype analysis and were able to determine that collateral flow controls endothelial gene expression patterns relevant to adaptive remodeling and that the resulting endothelial phenotypic changes have the capacity to modulate both smooth muscle gene expression and function.

Several of the genes characterized by genome-wide transcriptional profiling to be differentially regulated by the coronary collateral waveforms have previously been reported to regulate critical processes involved with adaptive remodeling. Specifically, the ACC waveform increased the expression of genes important for vessel tone (ENOS and VIP), vascular development/remodeling (TIE2, FGF2, DLL1, and JAG1), and maintenance of the arterial extracellular matrix (NOV and TIMP3). Vasodilation of collateral vessels has been observed to be dependent on endothelial nitric-oxide synthase during the initial stage of collateral adaptation (46), whereas in vivo evidence supports a role for the angiopoietin-Tie2 and Notch-Jag1/Dll1 receptor-ligand systems in both arterial development and adaptive coronary remodeling (4749). The ACC waveform also down-regulated multiple genes involved with angiogenesis/wound healing (ANGPT2, FBLN5, IL8, CTGF, CYR61, SEMA3A, TGFB2, and NRP1), inflammation (IL8 and MCP-1), and vasoconstriction (END-1) compared with the NCC waveform. Angiogenic and inflammatory genes are often associated with vascular remodeling, particularly in ischemic tissue or during pathological remodeling, but these processes may have detrimental effects to adaptive remodeling, since their stimuli and end-product vessel structure and function differ significantly. Consistent with the concept that EC genes down-regulated by ACC flow have detrimental effects on adaptive remodeling is the observation that constitutive overexpression of ANGPT2, a proangiogenic endothelial gene, in animals subjected to hind limb femoral artery ligation dramatically impairs collateral vessel remodeling (50).

Based on the differential expression of endothelial genes documented here, collateral flow has the ability to evoke distinct endothelial gene expression patterns whose functional contribution toward adaptive arteriogenesis may be through the stabilization and maintenance of large diameter arteries. Furthermore, when we delivered flow-mediated EC conditioned medium to cultured SMC, the SMC displayed gene expression patterns consistent with the assertion that collateral flow promotes vascular wall stabilization. In particular, we observed decreased expression of MMP-3 and increased expression of SMC MYOCD as well as the myocardin transcriptional targets CNN1 and αSMA. The latter observation indicates that collateral flow acting on the endothelium results in paracrine modulation of the contractile SMC phenotype, an important event associated with adaptive remodeling.

The transcription factor KLF2 emerged from the collateral flow-mediated EC transcriptional profile analysis as a potential key player in regulating an adaptive remodeling endothelial response based on evidence of its flow dependence and necessity to the function of the developing vessel wall. A member of the Kruppel family of zinc finger transcription factors, KLF2, has been shown to be tightly regulated by flow (31, 5153) and critical for controlling multiple endothelial phenotypes (31, 51, 54, 55). A number of other endothelial transcription factors were also regulated by the ACC waveform (supplemental material), but KLF2 had the strongest in vivo evidence indicating that the transcription factor may have a critical role in adaptive remodeling, since mice lacking KLF2 display lethal phenotypes of impaired vascular maturation and function. Both KLF2–/– mice and endothelium-specific knock-out of KLF2 in mice result in embryonic lethality, due either to hemorrhage (7, 11) or defects in vascular hemodynamics (8), respectively. Moreover, a recent report by Wu et al. (10) documented that the medial layer of vessels of KLF2–/– mice is poorly developed and that SMC of these mice display a patchy morphology with condensed nuclei when compared with wild-type mice. None of these mouse models, however, displayed impaired vasculogenic capacity, implying that the principal vascular defect associated with KLF2 loss involves ineffective regulation, potentially via the endothelium, of smooth muscle functions associated with vessel wall stability and reactivity.

This evidence prompted us to investigate the functional effect of EC KLF2 expression on interactions with SMC important for adaptive remodeling. Using three-dimensional SMC migration as a functional SMC read-out, our results show that EC KLF2 expression suppresses SMC migration and that this effect can be rescued by the exogenous delivery of CTGF, an EC-secreted factor whose expression is down-regulated by KLF2 at the transcriptional level. Furthermore, using a gel shift assay, we demonstrated that KLF2 can directly bind the CTGF proximal promoter sequence located at –1730 to –1706. This region of the 2-kb CTGF proximal promoter was one of two probes tested that contains two canonical CACCC KLF binding sites in tandem, whereas the other three probes contain a single CACCC site. Taken together, these data support the hypothesis that KLF2 has a role in adaptive remodeling by controlling EC-dependent SMC function and suggest that improper regulation of SMC migration may contribute to the vascular wall defects observed in KLF2 knock-out mice. Furthermore, the three-dimensional μFD migration assay as used in these experiments does not allow for cell contact between EC and SMC, indicating that the effect of EC KLF2 expression on SMC migration is partially due to the differential regulation and release of CTGF and other yet to be identified EC factors.

Overall, the results documented here demonstrate that collateral flow regulates cellular events critical for adaptive remodeling, including endothelial gene expression and endothelium-derived paracrine signals that modulate smooth muscle gene expression and functional phenotypes. In particular, endothelial genes regulated by collateral flow were found to control smooth muscle migration, a finding that has important implications for understanding how biomechanical forces influence endothelial interactions with smooth muscle cells. Finally, these data indicate that an integrated endothelial response to flow during adaptive remodeling controls critical events relevant to the blood vessel wall architecture.

Supplementary Material

[Supplemental Data]
M804524200_index.html (1.1KB, html)

Acknowledgments

We thank Kay Case and Vannessa Davis (Brigham and Women's Hospital Center for Excellence in Vascular Biology) for the isolation and culturing of the endothelial cells used in these experiments, Dr. Brett R. Blackman (University of Virginia) for insightful feedback on the EC-SMC interaction flow system during their early stages of conception and development, and Dr. Eugene Chen (University of Michigan) for kindly providing the CTGF promoter construct.

*

This work was supported, in whole or in part, by National Institutes of Health, NHLB, Grants RO1-HL7066686 and P50-HL56985 (to G. G.-C.) and National Institutes of Health, NIBIB, Grant BRP-EB003805 (to R. D. K.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

S⃞

The on-line version of this article (available at http://www.jbc.org) contains supplemental Tables S1–S3 and Figs. S1 and S2.

Footnotes

4

The abbreviations used are: TGF-β, transforming growth factor-β; ACC, adaptive remodeling coronary collateral (waveform); NCC, normal coronary collateral (waveform); μFD, microfluidic device; EC, endothelial cell; SMC, smooth muscle cell; EGM-2, endothelial growth medium-2; DAPI, 4′,6-diamidino-2-phenylindole; GFP, green fluorescent protein; GST, glutathione S-transferase.

References

  • 1.Heil, M., and Schaper, W. (2004) Coron. Artery Dis. 15 373–378 [DOI] [PubMed] [Google Scholar]
  • 2.Schaper, W., and Scholz, D. (2003) Arterioscler. Thromb. Vasc. Biol. 23 1143–1151 [DOI] [PubMed] [Google Scholar]
  • 3.Langille, B. L., and O'Donnell, F. (1986) Science 231 405–407 [DOI] [PubMed] [Google Scholar]
  • 4.Vita, J. A., Holbrook, M., Palmisano, J., Shenouda, S. M., Chung, W. B., Hamburg, N. M., Eskenazi, B. R., Joseph, L., and Shapira, O. M. (2008) Circulation 117 3126–3133 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Rudic, R. D., Shesely, E. G., Maeda, N., Smithies, O., Segal, S. S., and Sessa, W. C. (1998) J. Clin. Invest. 101 731–736 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Jain, R. K. (2003) Nat. Med. 9 685–693 [DOI] [PubMed] [Google Scholar]
  • 7.Kuo, C. T., Veselits, M. L., Barton, K. P., Lu, M. M., Clendenin, C., and Leiden, J. M. (1997) Genes Dev. 11 2996–3006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Lee, J. S., Yu, Q., Shin, J. T., Sebzda, E., Bertozzi, C., Chen, M., Mericko, P., Stadtfeld, M., Zhou, D., Cheng, L., Graf, T., MacRae, C. A., Lepore, J. J., Lo, C. W., and Kahn, M. L. (2006) Dev. Cell 11 845–857 [DOI] [PubMed] [Google Scholar]
  • 9.Lindahl, P., Hellstrom, M., Kalen, M., and Betsholtz, C. (1998) Curr. Opin. Lipidol. 9 407–411 [DOI] [PubMed] [Google Scholar]
  • 10.Wu, J., Bohanan, C. S., Neumann, J. C., and Lingrel, J. B. (2008) J. Biol. Chem. 283 3942–3950 [DOI] [PubMed] [Google Scholar]
  • 11.Wani, M. A., Means, R. T., Jr., and Lingrel, J. B. (1998) Transgenic Res. 7 229–238 [DOI] [PubMed] [Google Scholar]
  • 12.Majesky, M. W., Lindner, V., Twardzik, D. R., Schwartz, S. M., and Reidy, M. A. (1991) J. Clin. Invest. 88 904–910 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Song, R. H., Kocharyan, H. K., Fortunato, J. E., Glagov, S., and Bassiouny, H. S. (2000) Arterioscler. Thromb. Vasc. Biol. 20 923–930 [DOI] [PubMed] [Google Scholar]
  • 14.Corriere, M. A., Rogers, C. M., Eliason, J. L., Faulk, J., Kume, T., Hogan, B. L., and Guzman, R. J. (2008) J. Surg. Res. 145 142–149 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Sullivan, C. C., Du, L., Chu, D., Cho, A. J., Kido, M., Wolf, P. L., Jamieson, S. W., and Thistlethwaite, P. A. (2003) Proc. Natl. Acad. Sci. U. S. A 100 12331–12336 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Hirschi, K. K., Rohovsky, S. A., and D'Amore, P. A. (1998) J. Cell Biol. 141 805–814 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Lockman, K., Hinson, J. S., Medlin, M. D., Morris, D., Taylor, J. M., and Mack, C. P. (2004) J. Biol. Chem. 279 42422–42430 [DOI] [PubMed] [Google Scholar]
  • 18.Chiu, J. J., Chen, L. J., Chang, S. F., Lee, P. L., Lee, C. I., Tsai, M. C., Lee, D. Y., Hsieh, H. P., Usami, S., and Chien, S. (2005) Arterioscler. Thromb. Vasc. Biol. 25 963–969 [DOI] [PubMed] [Google Scholar]
  • 19.Hastings, N. E., Simmers, M. B., McDonald, O. G., Wamhoff, B. R., and Blackman, B. R. (2007) Am. J. Physiol. 293 C1824–C1833 [DOI] [PubMed] [Google Scholar]
  • 20.Sakamoto, N., Ohashi, T., and Sato, M. (2006) Ann. Biomed. Eng. 34 408–415 [DOI] [PubMed] [Google Scholar]
  • 21.Chien, S. (2007) Am. J. Physiol. 292 H1209–H1224 [DOI] [PubMed] [Google Scholar]
  • 22.Davies, P. F. (1995) Physiol. Rev. 75 519–560 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Takahashi, M., Ishida, T., Traub, O., Corson, M. A., and Berk, B. C. (1997) J. Vasc. Res. 34 212–219 [DOI] [PubMed] [Google Scholar]
  • 24.García-Cardeña, G., and Gimbrone, M. A., Jr. (2006) Handb. Exp. Pharmacol. 176 79–95 [DOI] [PubMed] [Google Scholar]
  • 25.Wolf, C., Cai, W. J., Vosschulte, R., Koltai, S., Mousavipour, D., Scholz, D., Afsah-Hedjri, A., Schaper, W., and Schaper, J. (1998) J. Mol. Cell Cardiol. 30 2291–2305 [DOI] [PubMed] [Google Scholar]
  • 26.Rockstroh, J., and Brown, B. G. (2002) Circulation 105 168–173 [DOI] [PubMed] [Google Scholar]
  • 27.Chaitman, B. R., Bourassa, M. G., Davis, K., Rogers, W. J., Tyras, D. H., Berger, R., Kennedy, J. W., Fisher, L., Judkins, M. P., Mock, M. B., and Killip, T. (1981) Circulation 64 360–367 [DOI] [PubMed] [Google Scholar]
  • 28.Heldt, T., Shim, E. B., Kamm, R. D., and Mark, R. G. (2002) J. Appl. Physiol. 92 1239–1254 [DOI] [PubMed] [Google Scholar]
  • 29.Dai, G., Kaazempur-Mofrad, M. R., Natarajan, S., Zhang, Y., Vaughn, S., Blackman, B. R., Kamm, R. D., García-Cardeña, G., and Gimbrone, M. A., Jr. (2004) Proc. Natl. Acad. Sci. U. S. A 101 14871–14876 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Watts, K. L., and Spiteri, M. A. (2004) Am. J. Physiol. 287 L1323–L1332 [DOI] [PubMed] [Google Scholar]
  • 31.Parmar, K. M., Larman, H. B., Dai, G., Zhang, Y., Wang, E. T., Moorthy, S. N., Kratz, J. R., Lin, Z., Jain, M. K., Gimbrone, M. A., Jr., and García-Cardeña, G. (2006) J. Clin. Invest. 116 49–58 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Comander, J., Natarajan, S., Gimbrone, M. A., Jr., and García-Cardeña, G. (2004) BMC Genomics 5 17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Zhao, X., Xia, Y., and Whitesides, G. M. (1997) Journal of Materials Chemistry 7 1069–1074 [Google Scholar]
  • 34.Bieker, J. J. (2001) J. Biol. Chem. 276 34355–34358 [DOI] [PubMed] [Google Scholar]
  • 35.Schreiner, W., Neumann, F., and Mohl, W. (1990) J. Biomed. Eng. 12 429–443 [DOI] [PubMed] [Google Scholar]
  • 36.Owens, G. K., Kumar, M. S., and Wamhoff, B. R. (2004) Physiol. Rev. 84 767–801 [DOI] [PubMed] [Google Scholar]
  • 37.Long, X., Bell, R. D., Gerthoffer, W. T., Zlokovic, B. V., and Miano, J. M. (2008) Arterioscler. Thromb. Vasc. Biol. 28 1505–1510 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Lee, E., Grodzinsky, A. J., Libby, P., Clinton, S. K., Lark, M. W., and Lee, R. T. (1995) Arterioscler. Thromb. Vasc. Biol. 15 2284–2289 [DOI] [PubMed] [Google Scholar]
  • 39.Newby, A. C. (2005) Physiol. Rev. 85 1–31 [DOI] [PubMed] [Google Scholar]
  • 40.Chatzizisis, Y. S., Coskun, A. U., Jonas, M., Edelman, E. R., Stone, P. H., and Feldman, C. L. (2007) Curr. Opin. Cardiol. 22 552–564 [DOI] [PubMed] [Google Scholar]
  • 41.Vickerman, V., Blundo, J., Chung, S., and Kamm, R. (2008) Lab on a Chip 8 1468–1477 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Cicha, I., Yilmaz, A., Klein, M., Raithel, D., Brigstock, D. R., Daniel, W. G., Goppelt-Struebe, M., and Garlichs, C. D. (2005) Arterioscler. Thromb. Vasc. Biol. 25 1008–1013 [DOI] [PubMed] [Google Scholar]
  • 43.Crean, J. K., Furlong, F., Finlay, D., Mitchell, D., Murphy, M., Conway, B., Brady, H. R., Godson, C., and Martin, F. (2004) FASEB J. 18 1541–1543 [DOI] [PubMed] [Google Scholar]
  • 44.Oemar, B. S., and Luscher, T. F. (1997) Arterioscler. Thromb. Vasc. Biol. 17 1483–1489 [DOI] [PubMed] [Google Scholar]
  • 45.Korshunov, V. A., Schwartz, S. M., and Berk, B. C. (2007) Arterioscler. Thromb. Vasc. Biol. 27 1722–1728 [DOI] [PubMed] [Google Scholar]
  • 46.Mees, B., Wagner, S., Ninci, E., Tribulova, S., Martin, S., van Haperen, R., Kostin, S., Heil, M., de Crom, R., and Schaper, W. (2007) Arterioscler. Thromb. Vasc. Biol. 27 1926–1933 [DOI] [PubMed] [Google Scholar]
  • 47.High, F. A., Lu, M. M., Pear, W. S., Loomes, K. M., Kaestner, K. H., and Epstein, J. A. (2008) Proc. Natl. Acad. Sci. U. S. A 105 1955–1959 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Jones, N., and Dumont, D. J. (2000) Cancer Metastasis Rev. 19 13–17 [DOI] [PubMed] [Google Scholar]
  • 49.Limbourg, A., Ploom, M., Elligsen, D., Sorensen, I., Ziegelhoeffer, T., Gossler, A., Drexler, H., and Limbourg, F. P. (2007) Circ. Res. 100 363–371 [DOI] [PubMed] [Google Scholar]
  • 50.Reiss, Y., Droste, J., Heil, M., Tribulova, S., Schmidt, M. H., Schaper, W., Dumont, D. J., and Plate, K. H. (2007) Circ. Res. 101 88–96 [DOI] [PubMed] [Google Scholar]
  • 51.Dekker, R. J., van Soest, S., Fontijn, R. D., Salamanca, S., de Groot, P. G., VanBavel, E., Pannekoek, H., and Horrevoets, A. J. (2002) Blood 100 1689–1698 [DOI] [PubMed] [Google Scholar]
  • 52.Huddleson, J. P., Ahmad, N., Srinivasan, S., and Lingrel, J. B. (2005) J. Biol. Chem. 280 23371–23379 [DOI] [PubMed] [Google Scholar]
  • 53.Huddleson, J. P., Srinivasan, S., Ahmad, N., and Lingrel, J. B. (2004) Biol. Chem. 385 723–729 [DOI] [PubMed] [Google Scholar]
  • 54.SenBanerjee, S., Lin, Z., Atkins, G. B., Greif, D. M., Rao, R. M., Kumar, A., Feinberg, M. W., Chen, Z., Simon, D. I., Luscinskas, F. W., Michel, T. M., Gimbrone, M. A., Jr., Garcia-Cardena, G., and Jain, M. K. (2004) J. Exp. Med. 199 1305–1315 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Dekker, R. J., Boon, R. A., Rondaij, M. G., Kragt, A., Volger, O. L., Elderkamp, Y. W., Meijers, J. C., Voorberg, J., Pannekoek, H., and Horrevoets, A. J. (2006) Blood 107 4354–4363 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

[Supplemental Data]
M804524200_index.html (1.1KB, html)
M804524200_1.pdf (468.5KB, pdf)

Articles from The Journal of Biological Chemistry are provided here courtesy of American Society for Biochemistry and Molecular Biology

RESOURCES